CD38 and neoplasm: Because radiolabelled daratumumab has limited tumour imaging ability at early time points, Wang et al. used gallium-68 to label Nb1053, a nanobody with a smaller molecular weight, which addressed the issue of mismatch of the half-lives between the mAb and copper-64/zirconium-89.225 [68Ga]Ga-NOTA-Nb1053 showed an average tumour uptake of 1.76 ± 0.305%ID/g, and has high specificity for CD38, with a tumour-to-muscle ratio of 10.90 and a tumour-to-bone ratio of 5.79.